N
Neerja Bhatla
Researcher at All India Institute of Medical Sciences
Publications - 278
Citations - 5722
Neerja Bhatla is an academic researcher from All India Institute of Medical Sciences. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 31, co-authored 221 publications receiving 4137 citations. Previous affiliations of Neerja Bhatla include AIIMS, New Delhi.
Papers
More filters
Journal ArticleDOI
The impact of a segregated team roster on obstetric and gynecology services in response to the COVID-19 pandemic in a tertiary care center in India.
Reeta Mahey,Aparna Sharma,Archana Kumari,Garima Kachhawa,Monica Gupta,Jyoti Meena,Neerja Bhatla +6 more
TL;DR: The impact of roster reorganization on ensuring uninterrupted services while providing necessary relief to healthcare workers (HCW) in the obstetrics department of a tertiary care center amid the COVID‐19 outbreak is studied.
Journal ArticleDOI
Thermal Balloon Endometrial Ablator: A Preclinical Safety and Effectiveness Study
TL;DR: The objective was to evaluate the preclinical safety and efficacy of the thermal balloon endometrial ablator (TBEA) and to establish a protocol for evaluating the TBEA in clinical practice.
Journal ArticleDOI
Development of a Questionnaire to Assess the Psychosocial Effects of COVID-19 on Peripartum Women
Archana Kumari,Keerthana Rajasekaran,Piyush Ranjan,Ashish Datt Upadhyay,Anju Singh,Rakesh K Chadda,Neerja Bhatla +6 more
TL;DR: A questionnaire to assess the psychosocial functioning of peripartum women in low middle-income countries and help perinatal mental health specialists to devise strategies to cope with the psychological impact of COVID-19-like pandemics on peripartsum women has good reliability and face, content, and construct validity.
Journal ArticleDOI
Prolapsed leiomyoma with severe haemorrhage after GnRH analogue therapy.
TL;DR: This case report highlights the importance of a cautious approach while administering GnRH analogue therapy in cases of submucous myoma as it can lead to life-threatening complications.
Journal ArticleDOI
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.
H Prudden,Sharon L. Achilles,Celina Schocken,Nathalie Broutet,Karen Canfell,Hiroki Akaba,Partha Basu,Neerja Bhatla,Zvavahera M. Chirenje,Sinead Delany-Moretlwe,Lynette Denny,Deepa Gamage,Rolando Herrero,Raymond Hutubessy,Luisa L. Villa,Raúl Murillo,John T. Schiller,Margaret Stanley,Marleen Temmerman,Fanghui Zhao,Gina Ogilvie,David C. Kaslow,Peter Dull,Sami L. Gottlieb +23 more
TL;DR: The potential value of TxV will depend on their degree of efficacy and how quickly they can be developed and implemented relative to ongoing scale-up of existing interventions as mentioned in this paper , and critical modelling needs for predicting the impact and cost-effectiveness.